



Appendix 4C – December 2018 Quarter

Brisbane, Australia 31st January 2019: Factor Therapeutics Limited (ASX: FTT), an Australian biotechnology company, has released its Appendix 4C for the December 2018 Quarter.

Key Points:

- Phase 2b clinical trial readout for venous leg ulcer healing delivered in November
- Clinical development activities for VF001 halted; and pipeline development halted
- Cost minimisation implemented immediately post-readout
- Current focus directed towards maintenance of the Company's IP portfolio and assessment of potential business opportunities, including new technology acquisitions

The Company held cash reserves at the end of the quarter of \$2.598 million. Quarterly operating expenditure during the quarter was \$1.479 million, in line with forecasts, with \$0.956 million on direct R&D activities.

During the quarter, the Company announced results of its Phase 2b clinical study, which showed the addition of VF001 did not provide a meaningful benefit over standard care alone for venous leg ulcer healing. Following this result further clinical development of VF001 and the Company's modest pipeline expansion activity were halted. Projected expenditure for the coming quarter is \$2.057 million, with the majority comprising contractual commitments with respect to this trial. The projected cash balance following these payments is \$0.541 million.

The Company's future cash position may also be impacted by receipt of a payment in April/May 2019 of approximately \$1.2 million under the federal government's Research and Development (R&D) Tax Incentive Scheme. The Company is in the process of preparing a claim for this payment as part of its annual tax return submission; however, receipt of these funds is subject to the usual review processes, particularly in relation to the Company's Overseas Finding.

Following the Phase 2b trial result the Company has managed the orderly completion of previous research and development activities and implemented significant cost minimisation initiatives. The Company's current focus is on maintaining its intellectual property portfolio while the Board completes assessment of a number of opportunities, including potential new technology acquisitions, and the Company's future direction.

Subsequent to the end of the quarter, the Company announced that Dr Rosalind Wilson had completed her tenure as CEO and been retained on a part-time consulting basis to continue to assist the Board in finalising this process.

About Factor Therapeutics

Factor Therapeutics Limited ("Factor") is a biomedical technology company that is developing treatments for acute and chronic wound healing applications. Factor is a clinical stage company with its lead program (VF001) in Phase II for the treatment of venous leg ulcers (VLUs). The company is also developing solutions for a variety of interventional wound care and serious orphan dermatology conditions. The company's platform technology originates from the Institute of Health and Biomedical Innovation at the Queensland University of Technology (QUT), Australia. Factor's shares are traded on the Australian Securities Exchange (ASX) under the ticker FTT. For more information, please visit <https://factor-therapeutics.com>

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/3/00. Amended 30/9/01, 24/10/05, 17/12/10, 1/09/16

Name of entity

FACTOR THERAPEUTICS LIMITED

ABN

45 101 955 088

Quarter ended ("current quarter")

31-December-2018

Consolidated statement of cash flows

	Current quarter	Year to date (9 months)
	\$A'000	\$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	17	110
1.2 Payments for		
(a) research and development	(956)	(6,334)
(b) product manufacturing and operating costs	(7)	(359)
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(367)	(1,723)
(f) administration and corporate costs	(182)	(1,049)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	16	57
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	1,251
1.8 Other (provide details if material)	-	-
1.9 Net cash from/(used in) operating activities	(1,479)	(8,047)

2. Cash flows from investing activities

2.1 Payments to acquire:		
(a) property, plant and equipment	-	(5)
(b) businesses (see item 10)	-	-
(c) investments	-	-

Consolidated statement of cash flows		Current quarter	Year to date
		\$A'000	(9 months) \$A'000
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.2	Proceeds from disposal of:		-
	(a) property, plant and equipment	1	1
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from/(used in) investing activities	1	(4)
3. Cash flows from financing activities			
3.1	Proceeds from issues of shares	-	4,172
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of shares, convertible notes or options	-	(339)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from/(used in) financing activities	-	3,833
4. Net increase / (decrease) in cash and cash equivalents for the period			
4.1	Cash and cash equivalents at beginning of quarter/year to date	4,047	6,642
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,479)	(8,047)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	1	(4)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	3,833

Consolidated statement of cash flows		Current quarter	Year to date
		\$A'000	(9 months) \$A'000
4.5	Effect of movement in exchange rates on cash held	29	174
4.6	Cash and cash equivalents at end of quarter	2,598	2,598

5. Reconciliation of cash and cash equivalents	Current quarter	Previous quarter
at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	\$A'000	\$A'000
5.1 Bank Balances	14	2,501
5.2 Call deposits	2,584	1,546
5.3 Bank overdrafts	-	-
5.4 Other (provide details)	-	-
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	2,598	4,047

6. Payments to directors of the entity and their associates	Current quarter
	\$A'000
6.1 Aggregate amount of payments to the parties included in item 1.2	(64)
6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	
Payments to directors includes directors fees and executive directors salaries.	

7. Payments to related entities of the entity and their associates	Current quarter
	\$A'000
7.1 Aggregate amount of payments to the parties included in item 1.2	-
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

8. Financing facilities available

Add notes as necessary for an understanding of the position

- 8.1 Loan facilities
8.2 Credit standby arrangements
8.3 Other (please specify)

Total facility amount at quarter end \$A'000	Total drawn at quarter end \$A'000
-	-
-	-
-	-

- 8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

--

9. Estimated cash outflows for next quarter

- 9.1 Research and development
9.2 Product manufacturing and operating costs
9.3 Advertising and marketing
9.4 Leased assets
9.5 Staff costs
9.6 Administration and corporate costs
9.7 Other - Transaction costs related to issue of shares
9.8 **Total estimated cash outflows**

\$A'000
1,655
2
-
-
129
271
-
2,057

**10. Acquisitions and disposals of business entities
(items 2.1(b) and 2.2(b) above)**

- 10.1 Name of entity
10.2 Place of incorporation or registration
10.3 Consideration for acquisition or disposal
10.4 Total net assets
10.5 Nature of business

Acquisitions	Disposals
N/A	N/A

Compliance statement

¹ This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

² This statement gives a true and fair view of the matters disclosed.

Sign here: Original signed
(Company Secretary)



Date: 31-January-2019

Print name: Melanie Farris

Notes

- 1 The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
- 2 If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3 Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.